Organon & Co. filed a Current Report on Form 8-K on October 30, 2026, to furnish supplemental non-GAAP financial metrics for the quarter ended September 30, 2026. The filing notes that the company has suspended its customary practice of issuing a quarterly earnings press release and hosting an earnings conference call due to a pending merger with Sun Pharmaceutical Industries Limited. As a result, the company is providing these supplemental measures in lieu of a traditional earnings release.
The supplemental information, included in Exhibit 99.1, presents financial metrics adjusted for specific items to assist in understanding the company’s financial performance. These non-GAAP measures include Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Gross Margin, Adjusted Gross Profit, Adjusted Net Income, Adjusted Diluted EPS, and Adjusted Selling, General and Administrative (SG&A) and Research and Development (R&D) expenses.
For the three months ended September 30, 2026, the company reported GAAP Gross Profit of $869 million and GAAP Diluted EPS of $0.60. The corresponding non-GAAP Adjusted Gross Profit was $938 million, and the Adjusted Diluted EPS was $0.94. The Adjusted EBITDA for the quarter was reported at $502 million, representing an Adjusted EBITDA margin of 31.9%.
The reconciliation tables detail the specific adjustments made to arrive at the non-GAAP figures. These adjustments include costs related to exiting manufacturing and supply agreements with Merck & Co., Inc., stock-based compensation, acquisition-related costs, and restructuring charges. The filing also notes that other costs for the quarter included $19 million related to the pending transaction with Sun Pharmaceutical Industries Limited.
